symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
QLGN,0.89,0.083135,22450,4496689,0,0.83-2.84,-0.01,"Qualigen Therapeutics, Inc.",USD,0001460702,US74754R1032,74754R103,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.qualigeninc.com,"Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.",Mr. Michael S. Poirier,Healthcare,US,31,760 918 9165,2042 Corte Del Nogal,Carlsbad,CA,92011,,0,https://financialmodelingprep.com/image-stock/QLGN.png,2015-06-23,False,False,True,False,False
